
Prime Medicine Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Prime Medicine Inc
Access all reports
Prime Medicine, Inc. is a biotechnology company specializing in next-generation gene editing technologies aimed at developing curative therapies for a broad range of genetic diseases. The company utilizes its proprietary Prime Editing platform, a highly precise and versatile method of correcting disease-causing mutations in DNA, targeting nearly 90% of known genetic mutations. Prime Medicine's therapeutic focus includes areas like hematology, immunology, liver, ocular, and neuromuscular diseases. The company is headquartered in Cambridge, Massachussetts, and its shares are listed on the NASDAQ.
Key slides for Prime Medicine Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Prime Medicine Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Prime Medicine Inc
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
PRME
Country
🇺🇸 United States